<DOC>
	<DOCNO>NCT02277223</DOCNO>
	<brief_summary>Background : Curcumin active phytochemical substance , use part human diet , anti-inflammatory anti-oxidative property demonstrate multiple experimental model colitis include positive effect maintenance remission adult ulcerative colitis ( UC ) patient . Objectives : To examine effect curcumin complementary medication induction maintenance therapy pediatric patient mild moderate ulcerative colitis . Design : A prospective , randomize , placebo-controlled study . Setting : Pediatric gastroenterology center . Participants : Children 6 year 18 year diagnose mild moderate UC plan receive either 5-ASA corticosteroid induction treatment . Main outcome measure : Disease activity define Pediatric Ulcerative Colitis Activity Index ( PUCAI ) 2 week 6 month . Secondary outcome measure : Effect curcumin treatment serum inflammatory marker , calprotectin fecal microbiota . Data analysis : Data collect analyzed use SPSS ( version 21.0 , SPSS , Inc. , Chicago , IL , USA ) . Fisher 's exact test use explore univariate association primary outcomes categorical variable . Associations continue variable primary outcome measure examine use ANOVA repeat measure . P-values &lt; 0.05 consider significant .</brief_summary>
	<brief_title>Curcumin Pediatric Ulcerative Colitis</brief_title>
	<detailed_description>Clinical efficacy induction maintenance medication pediatric UC limit cumulative long-term risk 20 % -30 % colectomy . Remission rate follow induction corticosteroid 5-amino-salicylic acid ( 5-ASA ) range 20 % 50 % . 5-ASA still regard first line induction maintenance therapy mild moderate UC child adult . 5-ASA also indicated maintenance therapy follow successful induction corticosteroid moderate severe disease . Still , steroid free clinical remission 1 year 5-ASA maintenance therapy report range 40 % 50 % . Management recurrent flare take 5-ASA medication involve repeated course corticosteroid change therapeutic regime include potent medication thiopurines carry increase risk significant adverse effect . Hence , improve efficacy induction maintenance treatment critical importance . Curcumin , active phytochemical substance anti-inflammatory property study extensively in-vitro experimental model colitis . In randomized controlled trial , perform adults quiescent disease , curcumin show effective concomitant treatment ( along 5-ASA ) maintenance remission . Therefore , aim ass efficacy concomitant curcumin maintenance therapy induction maintenance therapy pediatric UC patient mild moderate prospective randomize , placebo control trial . We hope study contribute understand potential benefit curcumin pediatric UC patient .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Curcumin</mesh_term>
	<criteria>1 . Diagnosis UC , establish presence accept clinical , radiologic , endoscopic histologic criterion . 2 . Age : 6 18 year ( inclusive ) . 3 . PUCAI 1065 enrollment 4 . Negative stool culture , parasites clostridium toxin 5 . Ability acceptance participate study follow study procedure , evidence parent/legal guardian signing write informed consent child provide assent . 1 . Acute severe UC ( PUCAI &gt; 65 point ) require IV corticosteroid . 2 . History two relapse 5ASA treatment . 3 . Pregnancy 4 . Sepsis active bacterial infection 5 . Fever &gt; 38.5 degree . 6 . Patients whose disease confine rectum ( i.e . proctitis ) . 7 . Patients crohn 's colitis IBD type unclassified ( IBDU ) accord Montreal classification . 8 . Rectal therapy ( suppository , foam , enema etc ) kind allow dose frequency remain stable previous 14 day prior screen visit . 9 . Known allergy 5ASA , salicylate , aminosalicylates . 10 . History recurrent pancreatitis . 11 . Existence current renal disease , screen blood urea nitrogen ( BUN ) creatinine value &gt; 1.5 time upper limit age appropriate normal .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>